Showing results (301-310 of 635) with videos related to
Sort By:
Pageof 64
ESC Heart Failure|January 13, 2021
Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trialCorrado De Marco, Brian L Claggett, Simon de Denus, et al.American Heart Journal|February 23, 2021
Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trialsMuhammad Shahzeb Khan, Soren Lund Kristensen, Muthiah Vaduganathan, et al.Circulation. Heart Failure|December 16, 2017
Predicting Risk in Patients Hospitalized for Acute Decompensated Heart Failure and Preserved Ejection Fraction: The Atherosclerosis Risk in Communities Study Heart Failure Community SurveillanceTonje Thorvaldsen, Brian L Claggett, Amil Shah, et al.Msphere|January 24, 2018
Targeted Phenotypic Screening in <i>Plasmodium falciparum</i> and <i>Toxoplasma gondii</i> Reveals Novel Modes of Action of Medicines for Malaria Venture Malaria Box MoleculesGowtham Subramanian, Meenakshi A Belekar, Anurag Shukla, et al.European Journal of Heart Failure|October 30, 2015
The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristicsHenry Krum, John J V McMurray, William T Abraham, et al.Journal of the American Heart Association|April 25, 2016
Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Marwa A Sabe, Brian Claggett, Emmanuel A Burdmann, et al.European Heart Journal|March 21, 2023
Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradoxJawad H Butt, Mark C Petrie, Pardeep S Jhund, et al.Cardiovascular Research|November 17, 2025
Obesity, aldosterone, and natriuretic peptide in patients with heart failure and reduced ejection fractionShingo Matsumoto, Jawad H Butt, Kieran F Docherty, et al.Journal of Vitreoretinal Diseases|July 17, 2025
Coring of Intravitreal Medication Vial Stoppers: A Report From the Research in Safety and Therapeutics Committee of the American Society of Retina SpecialistsFerhina S Ali, Eric W Schneider, Sruthi Arepalli, et al.Lancet (London, England)|January 25, 2016
Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trialBarry Greenberg, Javed Butler, G Michael Felker, et al.Pageof 64